Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Nov 21 2017

Full Issue

Nominee For HHS Post Raked In Millions As Top Pharma Executive

The newly released numbers are likely to ratchet up the scrutiny of Alex Azar, who is already facing criticism that he is too closely tied to the industry to be effective as the person regulating it.

The Associated Press: Health Nominee Reaped Big Earnings From Drug Industry Tenure

Newly disclosed financial records show that President Donald Trump's nominee to become Health and Human Services secretary reaped big earnings during his tenure as a top pharmaceutical executive. As a top drug industry veteran from 2007 to 2017, former Eli Lilly and Co. executive Alex Azar built a substantial financial portfolio now worth $9.5 million to $20.6 million, and he was paid nearly $2 million in his final year at the company. (Braun, 11/20)

The Hill: HHS Nominee Azar Made Millions Working For Drugmaker Lilly

Alex Azar, who was previously president of the U.S. division of pharmaceutical giant Eli Lilly and Co., has a net worth of at least $8.7 million, according to documents filed with the Office of Government Ethics and analyzed by The Hill. Azar was paid nearly $2 million in his final year at Eli Lilly, according to the documents, which only date back to the previous 12 months. The company also paid him a $1.6 million severance package. (Weixel, 11/20)

Politico: Azar Received Millions From Eli Lilly In Last Year, Disclosures Show

Multiple Senate Democrats, and independent Vermont Sen. Bernie Sanders, have already declared their opposition to Azar's nomination because of his ties to the drug industry. The Health, Education, Labor and Pensions Committee is set to hold the first confirmation hearing on his nomination Nov. 29. After leaving Indianapolis-based Lilly, Azar leaned heavily on his industry experience to find new work. He collected $46,500 in speaking fees for four events, including ones hosted by the National Association of Specialty Pharmacy and pharma-focused tech company Veeva Systems. Azar also valued his consulting firm's worth at between $15,001 and $50,000. The firm's clientele included the National Pharmaceutical Council and drug company UCB Inc. (Cancryn, 11/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF